NCT06170697 2023-12-20
Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
Clinical Trials
18 trialsNCT05576272 2023-11-22
A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma
Qilu Pharmaceutical Co., Ltd.
Phase 2/3 Unknown
NCT04156698 2023-08-09
Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma
Eye & ENT Hospital of Fudan University
Phase 2 Unknown
NCT04221516 2023-06-18
Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma
Nanfang Hospital, Southern Medical University
Phase 2 Unknown
NCT04586088 2023-05-06
Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure
Sun Yat-sen University
Phase 2 Unknown
NCT05724355 2023-02-13
CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC
Sun Yat-sen University
Phase 2 Unknown
NCT05549466 2023-02-08
Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC
Sun Yat-sen University
Phase 2 Unknown
NCT05611463 2022-11-10
CHANCE
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2 Unknown
NCT04978012 2022-06-07
Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy
Fudan University
Phase 2 Unknown
NCT04143984 2022-04-29
Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma
Shanghai Proton and Heavy Ion Center
Phase 2 Unknown
NCT04861467 2021-04-27
Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
ChineseAMS
Phase 2 Unknown
NCT04440917 2021-02-02
IMplus
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2 Unknown
NCT04612894 2020-11-03
Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer
Fudan University
Phase 2 Unknown
NCT04547088 2020-09-14
Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Unknown
NCT04548271 2020-09-14
Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Unknown
NCT04510818 2020-08-14
Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 2)
Ruijin Hospital
Phase 1 Unknown
NCT04405154 2020-05-28
A Study of Concomitant Camrelizumab With Chemoradiation for Locally Advanced Head and Neck Cancer
West China Hospital
Phase 2 Unknown
NCT04399785 2020-05-22
Phase II Study for Combination of Camrelizumab and SBRT in the First-line Treatment for R/M HNSCC
West China Hospital
Phase 2 Unknown